top of page
Long-time Chief Executive Officer Ben Silbermann of Pinterest would step down, handing over the reins of the social media platform to Google...

Stock Market

Google executive to take over as a new CEO of Pinterest

Top accounting firm Ernst & Young has been slammed with a record $100 million fine from the US government...

Stock Market

Accounting firm gets 100 million fine for faulty regulations

The Indian rupee slipped into a fresh low today and extended losses against the US dollar.


The rupee tumbled to a new low against the dollar in the midst of an increase in crude oil price

Wall Street saw a sharp fall at its closing in a broad sell-off. Consumers' worries over recession have sparked up...

Stock Market

Wall Street Lose Balance after recession strikes growth fear among consumers’

Soaring inflation may be pushing the US economy into a deep recession. Last week's 0.75% interest rate hike by the Federal Reserve...

Stock Market

Inflation ringing the recession bell - Mohammed Shaheen


28 Oct 2021

Research Shows Antidepressant Fluvoxamine Reduces Covid-19 Hospitalizations

The Index Today

In a recent clinical trial, researchers have determined that covid-19 patients who take fluvoxamine are less likely to be hospitalized in comparison to patients who don’t take antidepressants.

Fluvoxamine is a widely prescribed antidepressant falling in the category of selective serotonin reuptake inhibitors SSRI’s and is used to treat patients suffering from obsessive compulsive disorders or depression. The drug has been classified as a safe medication which has a course period of around 10 days.

Due to its low cost and easy availability, doctors are considering it as a safe alternative to covid-therapies. Other treatments such as monoclonal antibody treatments typically cost more and require patients to undergo an infusion.

Previous research conducted for the fluvoxamine suggests that the drug’s anti-inflammatory abilities help fight against covid, however doctors are still not sure of its exact functioning and is still being studied. Dr Edward Mills, a lead researcher and professor at McMaster University in Hamilton led a research trial with his colleagues to help understand the effects of the drug on covid patients.

The researchers gathered data to conclude patients who received fluvoxamine were 32% less likely to be hospitalized for covid. Dr Mills said, the research results have been published in the Lancet Global Health. However, more evidence is needed before the drug can be recommended as a safe alternative to fight against the deadly virus.

©Photo: nbcnews

Clay pottery with table linens
bottom of page